insights on current FDA-approved monoclonal antibodies against Ebola virus infection
O Tshiani Mbaya, P Mukumbayi… - Frontiers in immunology, 2021 - frontiersin.org
The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational …
[HTML][HTML] Why is there low morbidity and mortality of COVID-19 in Africa?
Three months since the detection of the first COVID-19 case in Africa, almost all countries of
the continent continued to report lower morbidity and mortality than the global trend …
the continent continued to report lower morbidity and mortality than the global trend …
Human antibodies for viral infections
JE Crowe Jr - Annual review of immunology, 2022 - annualreviews.org
Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …
but the full potential to use passive immunization for infectious diseases has yet to be …
Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever
JM Fels, DP Maurer, AS Herbert, AS Wirchnianski… - Cell, 2021 - cell.com
Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority
pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific …
pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific …
A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
D Haslwanter, ME Dieterle, AZ Wec, CM O'brien… - Mbio, 2021 - Am Soc Microbiol
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization
Structural principles underlying the composition of protective antiviral monoclonal antibody
(mAb) cocktails are poorly defined. Here, we exploited antibody cooperativity to develop a …
(mAb) cocktails are poorly defined. Here, we exploited antibody cooperativity to develop a …
Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection
Passive administration of monoclonal antibodies (mAbs) is a promising therapeutic
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses
Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
Combination therapy protects macaques against advanced Marburg virus disease
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising
monotherapies for many viruses, including members of the genera Marburgvirus and …
monotherapies for many viruses, including members of the genera Marburgvirus and …